- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04586426
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)
April 23, 2024 updated by: Janssen Research & Development, LLC
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Multiple myeloma is a malignant plasma cell disorder characterized by production of monoclonal proteins (M proteins), which are comprised of pathologic immunoglobulins (Ig) or fragments of such, which have subsequently lost their normal function.
Rationale for combining talquetamab and teclistamab is the targeting of multiple proteins on the surface of multiple myeloma cells resulting in cell lysis.
This study consists of 3 periods: screening phase (up to 28 days), treatment phase (start of study drug administration and continues until the completion of the end of treatment [EOT] visit); and a post-treatment follow-up phase (after end of treatment and up to 16 weeks after last dose of study drug(s) for each participant).
End of study is defined as 2 years after the last participant has received his or her initial dose of the treatment combination.
Total duration of study is Approximately 5 years.
Efficacy, safety, pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed at specified time points during this study.
Participants safety and study conduct will be monitored throughout the study.
Study Type
Interventional
Enrollment (Estimated)
208
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Fitzroy, Australia, 3065
- Recruiting
- St. Vincent's Hospital Melbourne
-
Perth, Australia, 6000
- Recruiting
- Royal Perth Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Recruiting
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Alberta Health Services
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X6
- Recruiting
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Centre
-
-
-
-
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Center
-
Ramat Gan, Israel, 52621
- Recruiting
- Sheba Medical Center
-
Tel-Aviv, Israel, 64239
- Recruiting
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Kanazawa, Japan, 920-8641
- Recruiting
- Kanazawa University Hospital
-
Nagoya, Japan, 467 8602
- Recruiting
- Nagoya City University Hospital
-
Osaka, Japan, 565-0871
- Recruiting
- Osaka University Hospital
-
Sendai shi, Japan, 980 8574
- Recruiting
- Tohoku University Hospital
-
Shibuya, Japan, 150-8935
- Recruiting
- Japanese Red Cross Medical Center
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Seoul, Korea, Republic of, 06591
- Recruiting
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Badalona, Spain, 08916
- Recruiting
- Hosp. Univ. Germans Trias I Pujol
-
Barcelona, Spain, 08036
- Recruiting
- Hosp. Clinic de Barcelona
-
L Hospitalet De Llobregat, Spain, 08908
- Recruiting
- Inst. Cat. Doncologia-H Duran I Reynals
-
Madrid, Spain, 28040
- Recruiting
- Hosp. Univ. Fund. Jimenez Diaz
-
Madrid, Spain, 28041
- Recruiting
- UNIV. HOSP. October 12
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Univ. de Navarra
-
Salamanca, Spain, 37007
- Recruiting
- Hosp. Clinico Univ. de Salamanca
-
Santander, Spain, 39008
- Recruiting
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham, Comprehensive Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- University of Arkansas for Medical Sciences
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63130
- Recruiting
- Washington University in St. Louis
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Atrium Health
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Part 1 and 2: Participant could not tolerate or has disease that is relapsed or refractory to established therapies, including the last line of therapy. Part 3: (a) Relapsed or refractory disease, and exposed to a PI, IMiD, and an anti-CD38 mAb; (b) Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 at screening and immediately before the start of study drug administration. Part 3: ECOG performance status grade of 0, 1, or 2 at screening and immediately before the start of study drug administration
Exclusion Criteria:
- All Parts: Targeted therapy, epigenetic therapy, or treatment with an investigational treatment or an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less. Part 3: prior BCMA targeted bispecific antibody therapy; prior GPRC5D targeted therapy
- All Parts: Allogeneic stem cell transplant within 6 months before the first dose of study treatment.
- All Parts: Central nervous system involvement or clinical signs of meningeal involvement of multiple myeloma.
- All Parts: Active plasma cell leukemia (greater than [>]2.0*10^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M- protein, and skin changes), or primary amyloid light chain amyloidosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Escalation
Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
|
Talquetamab will be administered by subcutaneous (SC) injection.
Other Names:
Teclistamab will be administered by SC injection.
Other Names:
Daratumumab will be administered by SC injection.
|
Experimental: Part 2: Dose Expansion
Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the recommended Phase 2 regimen (s) (RP2R[s]) of the study treatment identified in Part 1.
|
Talquetamab will be administered by subcutaneous (SC) injection.
Other Names:
Teclistamab will be administered by SC injection.
Other Names:
Daratumumab will be administered by SC injection.
|
Experimental: Part 3: Phase 2
Participants will receive teclistamab + talquetamab combination therapy, at the RP2R selected from Part 1 and Part 2.
|
Talquetamab will be administered by subcutaneous (SC) injection.
Other Names:
Teclistamab will be administered by SC injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of Participants with Dose Limiting Toxicity (DLT)
Time Frame: Approximately 5 years
|
The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.
|
Approximately 5 years
|
Part 1: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Time Frame: Approximately 5 years
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
|
Approximately 5 years
|
Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
Time Frame: Approximately 5 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product, is medically important.
|
Approximately 5 years
|
Part 2: Number of Participants with Adverse Events and SAEs by Severity
Time Frame: Approximately 5 years
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
|
Approximately 5 years
|
Part 3: Overall Response Rate (ORR)
Time Frame: Approximately 5 years
|
ORR is defined as the percentage of participants who have a partial response (PR) or better according Independent Review Committees (IRC).
|
Approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parts 1, 2 and 3: Serum Concentration of Talquetamab
Time Frame: Approximately 5 years
|
Serum samples will be analyzed to determine concentrations of talquetamab using a validated, specific, and sensitive immunoassay method.
|
Approximately 5 years
|
Parts 1, 2 and 3: Serum Concentration of Teclistamab
Time Frame: Approximately 5 years
|
Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive immunoassay method.
|
Approximately 5 years
|
Part 1 and Part 2: Serum Concentration of Daratumumab
Time Frame: Approximately 5 years
|
Serum samples will be analyzed to determine concentrations of daratumumab using a validated, specific, and sensitive immunoassay method.
|
Approximately 5 years
|
Parts 1, 2 and 3: Number of Participants with Anti-Drug Antibodies to Talquetamab
Time Frame: Approximately 5 years
|
Number of participants with anti-drug antibodies to talquetamab will be assessed.
|
Approximately 5 years
|
Parts 1, 2 and 3: Number of Participants with Anti-Drug Antibodies to Teclistamab
Time Frame: Approximately 5 years
|
Number of participants with anti-drug antibodies to teclistamab will be assessed.
|
Approximately 5 years
|
Part 1 and Part 2: Number of Participants with Anti-Drug Antibodies to Daratumumab
Time Frame: Approximately 5 years
|
Number of participants with anti-drug antibodies to daratumumab will be assessed.
|
Approximately 5 years
|
Part 1 and Part 2: Overall Response Rate (ORR)
Time Frame: Approximately 5 years
|
ORR is defined as the percentage of participants who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.
|
Approximately 5 years
|
Parts 1, 2 and 3: Very Good Partial Response (VGPR) or Better Response Rate
Time Frame: Approximately 5 years
|
VGPR or better response rate (sCR+CR+VGPR) is defined as the percentage of participants who achieve a VGPR or better response according to the IMWG criteria.
|
Approximately 5 years
|
Parts 1, 2 and 3: Complete Response (CR) or Better Response Rate
Time Frame: Approximately 5 years
|
CR or better response rate (sCR+CR) is defined as the percentage of participants who achieve a CR or better response according to the IMWG criteria.
|
Approximately 5 years
|
Parts 1, 2 and 3: Duration of Response (DOR)
Time Frame: Approximately 5 years
|
DOR will be calculated among responders (with PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.
|
Approximately 5 years
|
Parts 1, 2 and 3: Time to Response
Time Frame: Approximately 5 years
|
Time to response is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
|
Approximately 5 years
|
Part 3: Progression free Survival (PFS)
Time Frame: Approximately 5 years
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.
|
Approximately 5 years
|
Part 3: Overall Survival (OS)
Time Frame: Approximately 5 years
|
OS is measured from the date of first dose to the date of the participant's death.
|
Approximately 5 years
|
Part 3: Number of Participants with Adverse Events
Time Frame: Approximately 5 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
|
Approximately 5 years
|
Part 3: Number of Participants with Adverse Events by Severity
Time Frame: Approximately 5 years
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
|
Approximately 5 years
|
Part 1, 2 and 3: Stringent Complete Response (sCR) Rate
Time Frame: Approximately 5 years
|
sCR rate is defined as the percentage of participants who achieve a sCR according to the IMWG criteria.
|
Approximately 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2020
Primary Completion (Estimated)
June 27, 2025
Study Completion (Estimated)
August 29, 2025
Study Registration Dates
First Submitted
October 12, 2020
First Submitted That Met QC Criteria
October 12, 2020
First Posted (Actual)
October 14, 2020
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Daratumumab
Other Study ID Numbers
- CR108901
- 2019-004124-38 (EudraCT Number)
- 64007957MMY1003 (Other Identifier: Janssen Research & Development, LLC)
- 2023-503439-16-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Talquetamab
-
Memorial Sloan Kettering Cancer CenterJanssen PharmaceuticalsRecruitingMultiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingHematological MalignanciesUnited States, Netherlands, Spain, Belgium
-
Janssen Research & Development, LLCNo longer availableRelapsed or Refractory Multiple MyelomaBelgium, Iceland, Portugal, Slovenia
-
Janssen Research & Development, LLCApproved for marketingRelapsed or Refractory Multiple MyelomaBrazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
-
Janssen Research & Development, LLCRecruitingHematological MalignanciesUnited States, Belgium, Korea, Republic of, China, Germany, Israel, Spain, Netherlands, Japan, France, Poland
-
Janssen Pharmaceutical K.K.Active, not recruiting
-
Janssen Research & Development, LLCWithdrawnRelapsed/ Refractory Multiple MyelomaUnited States, Poland
-
Carl Ola Landgren, MD, PhDJanssen Scientific Affairs, LLCRecruitingMultiple MyelomaUnited States
-
CelgeneRecruitingMultiple MyelomaUnited States, France, Germany, Spain, United Kingdom, Italy
-
Janssen Research & Development, LLCRecruitingRelapsed/ Refractory Multiple MyelomaUnited States, Germany, Spain, France